Core Viewpoint - The announcement by Chongqing Laimei Pharmaceutical Co., Ltd. indicates that major shareholder Qiu Yu will passively reduce his shareholding due to overdue debts related to a pledged securities repurchase agreement with Guohai Securities, but this will not affect the company's control or ongoing operations [1][4]. Group 1: Shareholding and Reduction Plan - As of the disclosure date, Qiu Yu holds 110,700,054 shares of Laimei Pharmaceutical, accounting for 10.48% of the total share capital [2]. - The reduction involves the forced sale of 54 shares through centralized bidding, with a reduction period of three months from the announcement date, and a limit of 1% of the total shares within any consecutive 90 days [2]. - The shares being reduced were originally held before the company's IPO, subscribed during a major asset restructuring in 2013, and include shares from historical equity distributions [2]. Group 2: Compliance and Background - The shares subject to reduction were pledged in a repurchase agreement as early as August 23, 2017, and the pledge registration was completed by August 27, 2023 [3]. - Laimei Pharmaceutical emphasizes that the passive reduction complies with relevant regulations and does not involve any violations [3]. Group 3: Impact on Company - The company asserts that the reduction will not lead to a change in control, as Qiu Yu has delegated voting rights to Zhongheng Group, which will maintain the governance structure [4]. - Even if the reduced shares are acquired by third parties, it will only affect the voting rights held by Zhongheng Group without altering the company's controlling shareholder [4]. - The company will monitor the reduction process and fulfill disclosure obligations as required [4].